Biomea Fusion Q1 loss $29.3M; realigns on diabetes/obesity, cuts workforce 35%

Biomea Fusion, Inc.

2025-Q1 EPS reported -$0.80

Q1 net loss $29.3M ($36.2M cash); cash runway extended into Q4 2025.
Strategic realignment: 35% workforce reduction; focus on icovamenib and oral GLP-1 BMF-650.
R&D expenses $22.9M (down from $33.8M YoY); G&A $6.8M (down from $7.3M).
Phase II COVALENT-111 52-week T2D data expected H2 2025; Type-C meeting with FDA planned.
Interim CEO Mick Hitchcock appointed March 2025; oncology BMF-500 partnership exploration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.